Stay updated with breaking news from Edmond Chan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New UBC research reveals a safe path to overcoming food allergies for older children and others who can’t risk consuming allergens orally to build up their resistance.
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati...
Media contact: Investor contact: ...
Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the European Commission has approved a type II variant for Carvykti . This latest approval is for the treatment of...
Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.